The neurostimulation devices market would grow at a CAGR of 11.57% over the predicted time frame. The market is expected to increase in value from US$ 9.96 Bn in 2022 to US$ 23.9 Bn in 2030.
Key Takeaways:
- North America neurostimulation devices market size was reached at USD 7.2 billion in 2021.
- North America garnered market share of around 61% in 2021 and it is expected to grow at a CAGR of 10.4% from 2022 to 2030.
- By product, the germany neurostimulation devices market was valued at USD 148 million in 2021 with a CAGR of 14% over timeframe.
- The spinal cord trigger product segment contributed 56% revenue share in 20201.
- Based on product, the deep brain stimulator (DBS) segment is expected to grow at a CAGR of 12.8% from 2022 to 2030.
- The pain management application segment drove the market in 2021 and represented the greatest income portion of over 69%.
The on neurostimulation devices Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/1853
Report Scope of the Hormone Replacement Therapy Market
| Report Coverage | Details |
| Market Size by 2030 | USD 23.9 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 11.57% |
| North America Market Share in 2021 | 61% |
| Spinal Cord Trigger Product Segment Market Share in 2021 | 56% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Technology, Disease Pathology, Product, Application, End Users, Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Neurostimulation devices Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Neurostimulation devices market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Neurostimulation devices market are included as given below:
Neurostimulation devices Market Key Players
- Medtronic PLC
- Cyberonics
- Boston Scientific Corp.
- St. Jude Medical, Inc.
- Nevro Corp.
- MicroPort Scientific Corporation (China),
- Kaneka Corp. (Japan)
- Integer Holdings Corporation
- BALT (France)
- Perflow Medical
- Phenox GmbH (Germany)
- Sensome (France)
Market Segments
By Technology
- Aneurysm coiling & embolization devices
- Embolic coils
- Bare detachable coils
- Coated detachable coils
- Flow diversion devices
- Liquid embolic agents
- Embolic coils
- Cerebral balloon angioplasty & Stenting systems
- Carotid artery stents
- Embolic protection devices
- Balloon catheters
- Support devices
- Microcatheters
- Guidewires
- Neurothrombectomy devices
- Clot retrievals
- Suction & aspiration devices
- Snares
By Disease Pathology
- Ischemic Strokes
- Cerebral Aneuryms
- Carotid Artery Stenosis
- Arteriovenous Malformations and Fistulas
- Other Diseases
By Product
- Spinal Cord Stimulator
- Deep Brain Stimulator
- Sacral Nerve Stimulator
- Vagus Nerve Stimulator
- Gastric Electric Stimulator
By Application
- Pain Management
- Epilepsy
- Essential Tremor
- Urinary and Fecal Incontinence
- Depression
- Dystonia
- Gastroparesis
- Parkinson’s Disease
- Others
By End Users
- Hospitals & Surgical Centers
- Ambulatory Care Centers
- Research Laboratories & Academic Institutes
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global neurostimulation devices market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the neurostimulation devices market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Neurostimulation Devices Market
5.1. COVID-19 Landscape: Neurostimulation Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Neurostimulation Devices Market, By Technology
8.1. Neurostimulation Devices Market, by January, 2022-2030
8.1.1. Aneurysm coiling & embolization devices
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Cerebral balloon angioplasty & Stenting systems
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Support devices
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Neurothrombectomy devices
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Neurostimulation Devices Market, By Disease Pathology
9.1. Neurostimulation Devices Market, by February, 2022-2030
9.1.1. Ischemic Strokes
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Cerebral Aneuryms
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Carotid Artery Stenosis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Arteriovenous Malformations and Fistulas
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Other Diseases
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Neurostimulation Devices Market, By Product
10.1. Neurostimulation Devices Market, by March, 2022-2030
10.1.1. Spinal Cord Stimulator
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Deep Brain Stimulator
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Sacral Nerve Stimulator
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Vagus Nerve Stimulator
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Gastric Electric Stimulator
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Neurostimulation Devices Market, By Application
11.1. Neurostimulation Devices Market, by April, 2022-2030
11.1.1. Pain Management
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Epilepsy
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Essential Tremor
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Urinary and Fecal Incontinence
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Depression
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Dystonia
11.1.6.1. Market Revenue and Forecast (2017-2030)
11.1.7. Gastroparesis
11.1.7.1. Market Revenue and Forecast (2017-2030)
11.1.8. Parkinson’s Disease
11.1.8.1. Market Revenue and Forecast (2017-2030)
11.1.9. Others
11.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Neurostimulation Devices Market, By End Users
12.1. Neurostimulation Devices Market, by May, 2022-2030
12.1.1. Hospitals & Surgical Centers
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Ambulatory Care Centers
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Research Laboratories & Academic Institutes
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Neurostimulation Devices Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by January (2017-2030)
13.1.2. Market Revenue and Forecast, by February (2017-2030)
13.1.3. Market Revenue and Forecast, by March (2017-2030)
13.1.4. Market Revenue and Forecast, by April (2017-2030)
13.1.5. Market Revenue and Forecast, by May (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by January (2017-2030)
13.1.6.2. Market Revenue and Forecast, by February (2017-2030)
13.1.6.3. Market Revenue and Forecast, by March (2017-2030)
13.1.6.4. Market Revenue and Forecast, by April (2017-2030)
13.1.7. Market Revenue and Forecast, by May (2017-2030)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by January (2017-2030)
13.1.8.2. Market Revenue and Forecast, by February (2017-2030)
13.1.8.3. Market Revenue and Forecast, by March (2017-2030)
13.1.8.4. Market Revenue and Forecast, by April (2017-2030)
13.1.8.5. Market Revenue and Forecast, by May (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by January (2017-2030)
13.2.2. Market Revenue and Forecast, by February (2017-2030)
13.2.3. Market Revenue and Forecast, by March (2017-2030)
13.2.4. Market Revenue and Forecast, by April (2017-2030)
13.2.5. Market Revenue and Forecast, by May (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by January (2017-2030)
13.2.6.2. Market Revenue and Forecast, by February (2017-2030)
13.2.6.3. Market Revenue and Forecast, by March (2017-2030)
13.2.7. Market Revenue and Forecast, by April (2017-2030)
13.2.8. Market Revenue and Forecast, by May (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by January (2017-2030)
13.2.9.2. Market Revenue and Forecast, by February (2017-2030)
13.2.9.3. Market Revenue and Forecast, by March (2017-2030)
13.2.10. Market Revenue and Forecast, by April (2017-2030)
13.2.11. Market Revenue and Forecast, by May (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by January (2017-2030)
13.2.12.2. Market Revenue and Forecast, by February (2017-2030)
13.2.12.3. Market Revenue and Forecast, by March (2017-2030)
13.2.12.4. Market Revenue and Forecast, by April (2017-2030)
13.2.13. Market Revenue and Forecast, by May (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by January (2017-2030)
13.2.14.2. Market Revenue and Forecast, by February (2017-2030)
13.2.14.3. Market Revenue and Forecast, by March (2017-2030)
13.2.14.4. Market Revenue and Forecast, by April (2017-2030)
13.2.15. Market Revenue and Forecast, by May (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by January (2017-2030)
13.3.2. Market Revenue and Forecast, by February (2017-2030)
13.3.3. Market Revenue and Forecast, by March (2017-2030)
13.3.4. Market Revenue and Forecast, by April (2017-2030)
13.3.5. Market Revenue and Forecast, by May (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by January (2017-2030)
13.3.6.2. Market Revenue and Forecast, by February (2017-2030)
13.3.6.3. Market Revenue and Forecast, by March (2017-2030)
13.3.6.4. Market Revenue and Forecast, by April (2017-2030)
13.3.7. Market Revenue and Forecast, by May (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by January (2017-2030)
13.3.8.2. Market Revenue and Forecast, by February (2017-2030)
13.3.8.3. Market Revenue and Forecast, by March (2017-2030)
13.3.8.4. Market Revenue and Forecast, by April (2017-2030)
13.3.9. Market Revenue and Forecast, by May (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by January (2017-2030)
13.3.10.2. Market Revenue and Forecast, by February (2017-2030)
13.3.10.3. Market Revenue and Forecast, by March (2017-2030)
13.3.10.4. Market Revenue and Forecast, by April (2017-2030)
13.3.10.5. Market Revenue and Forecast, by May (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by January (2017-2030)
13.3.11.2. Market Revenue and Forecast, by February (2017-2030)
13.3.11.3. Market Revenue and Forecast, by March (2017-2030)
13.3.11.4. Market Revenue and Forecast, by April (2017-2030)
13.3.11.5. Market Revenue and Forecast, by May (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by January (2017-2030)
13.4.2. Market Revenue and Forecast, by February (2017-2030)
13.4.3. Market Revenue and Forecast, by March (2017-2030)
13.4.4. Market Revenue and Forecast, by April (2017-2030)
13.4.5. Market Revenue and Forecast, by May (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by January (2017-2030)
13.4.6.2. Market Revenue and Forecast, by February (2017-2030)
13.4.6.3. Market Revenue and Forecast, by March (2017-2030)
13.4.6.4. Market Revenue and Forecast, by April (2017-2030)
13.4.7. Market Revenue and Forecast, by May (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by January (2017-2030)
13.4.8.2. Market Revenue and Forecast, by February (2017-2030)
13.4.8.3. Market Revenue and Forecast, by March (2017-2030)
13.4.8.4. Market Revenue and Forecast, by April (2017-2030)
13.4.9. Market Revenue and Forecast, by May (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by January (2017-2030)
13.4.10.2. Market Revenue and Forecast, by February (2017-2030)
13.4.10.3. Market Revenue and Forecast, by March (2017-2030)
13.4.10.4. Market Revenue and Forecast, by April (2017-2030)
13.4.10.5. Market Revenue and Forecast, by May (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by January (2017-2030)
13.4.11.2. Market Revenue and Forecast, by February (2017-2030)
13.4.11.3. Market Revenue and Forecast, by March (2017-2030)
13.4.11.4. Market Revenue and Forecast, by April (2017-2030)
13.4.11.5. Market Revenue and Forecast, by May (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by January (2017-2030)
13.5.2. Market Revenue and Forecast, by February (2017-2030)
13.5.3. Market Revenue and Forecast, by March (2017-2030)
13.5.4. Market Revenue and Forecast, by April (2017-2030)
13.5.5. Market Revenue and Forecast, by May (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by January (2017-2030)
13.5.6.2. Market Revenue and Forecast, by February (2017-2030)
13.5.6.3. Market Revenue and Forecast, by March (2017-2030)
13.5.6.4. Market Revenue and Forecast, by April (2017-2030)
13.5.7. Market Revenue and Forecast, by May (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by January (2017-2030)
13.5.8.2. Market Revenue and Forecast, by February (2017-2030)
13.5.8.3. Market Revenue and Forecast, by March (2017-2030)
13.5.8.4. Market Revenue and Forecast, by April (2017-2030)
13.5.8.5. Market Revenue and Forecast, by May (2017-2030)
Chapter 14. Company Profiles
14.1. Medtronic PLC
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Cyberonics
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Boston Scientific Corp.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. St. Jude Medical, Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Nevro Corp.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. MicroPort Scientific Corporation
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Kaneka Corp
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Integer Holdings Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. BALT
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Perflow Medical
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments